PROOFWAKE BIO

WORKED EXAMPLE · PUBLIC RECORDS

STAR-0310 for eczema

One public record points to a company to call. The clinical evidence still leaves a much bigger question.

Keep going: ask IGI

Public sources checked November 21, 2026. This is a decision about what to check next for a business lead, not medical, legal or investment advice.

1. What happened in people?

Confirmed in the trial record

The Phase 1 study enrolled healthy adults, not people with eczema. It cannot tell us whether the drug helps eczema. An early study abstract describes 32 people randomized in the initial report. That figure is for the abstract, not necessarily the entire study.

2. Why did the work stop?

Reported by the company

BioCryst said on November 4, 2026 it discontinued its development of STAR-0310 to focus its resources on rare diseases. That explains BioCryst’s stated decision. It does not establish that the drug works or that there were no other concerns.

3. Who might control the rights or data?

Reported by the company; details not verified

Glenmark’s November earnings call says full licensing rights were to return to Ichnos Glenmark Innovation (IGI) effective November 4 and that IGI was considering paths including partnerships. The IGI pipeline lists the program. Territory, terms, current deal status and access to the full study report were not verified.

4. What is the next useful question?

Proofwake’s first-screen judgment

Ask IGI: “Are you discussing licenses for STAR-0310, and what human study reports can an interested partner see?” One short inquiry is justified. Do not spend on a larger review until there is a clear answer.

Ask about a brief for your lead Compare all three examples